Floatz Rating
B56/100
Confidence
Indicative
Sponsor
Capital Medical University
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07509645CT.gov Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke | — | Recruiting | — | — | — |
NCT07263776CT.gov Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2 | — | Active Not Recruiting | — | — | — |
NCT06447701CT.gov Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis | — | Not Yet Recruiting | — | — | — |
NCT06238024CT.gov Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ischemic Stroke
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tocilizumab (this asset) | Capital Medical University | P3 | B · 56 |
| Ticagrelor | Sichuan Provincial People's Hospital | P4 | BBB |
| Cilostazol | Stanford University | P4 | BBB |
| Compound Edaravone | Nanfang Hospital, Southern Medical University | P4 | BBB |
| 3-N-BUTYLPHTHALIDE | Nanfang Hospital, Southern Medical University | P4 | BBB |
| Argatroban | Second Affiliated Hospital, School of Medicine, Zhejiang University | P4 | BBB |
| Tenecteplase | Hackensack Meridian Health | P4 | BBB |
| Clopidogrel | Nanfang Hospital, Southern Medical University | P4 | BB |
| Aspirin | Nanfang Hospital, Southern Medical University | P4 | BB |
+42 more in the Ischemic Stroke cohort
Other indications for Tocilizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rheumatoid Arthritis | — | P3 | BB · 66 |
| COVID-19 | — | P3 | BB · 65 |
| Acute Chest Syndrome | — | P3 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tocilizumab in Ischemic Stroke. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tocilizumab-ischemic-stroke
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →